Cargando…

Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives

BACKGROUND: Value of information (VOI) is a tool that can be used to inform decisions concerning additional research in healthcare. VOI estimates the value of obtaining additional information and indicates the optimal design for additional research. Although it is recognized as good practice in hand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bindels, Jill, Ramaekers, Bram, Ramos, Isaac Corro, Mohseninejad, Leyla, Knies, Saskia, Grutters, Janneke, Postma, Maarten, Al, Maiwenn, Feenstra, Talitha, Joore, Manuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766221/ https://www.ncbi.nlm.nih.gov/pubmed/26578403 http://dx.doi.org/10.1007/s40273-015-0346-z

Ejemplares similares

Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
por: van Asselt, Thea, et al.
Publicado: (2017)

Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models
por: Grimm, Sabine E., et al.
Publicado: (2019)

Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases”)
por: Grimm, Sabine E., et al.
Publicado: (2021)

Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases”)
por: Grimm, Sabine E., et al.
Publicado: (2021)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2015)

State of the ART? Two New Tools for Risk Communication in Health Technology Assessments
por: Grimm, Sabine E., et al.
Publicado: (2021)

The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling
por: van Voorn, George A. K., et al.
Publicado: (2015)

Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer
por: Pouwels, Xavier Ghislain Léon Victor, et al.
Publicado: (2017)

Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
por: Otten, Thomas Michael, et al.
Publicado: (2023)

The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios
por: Franken, Margreet G, et al.
Publicado: (2018)

A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process
por: Li, Fang, et al.
Publicado: (2022)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Association between lung function and exacerbation frequency in patients with COPD
por: Hoogendoorn, Martine, et al.
Publicado: (2010)

More than cost‐effectiveness? Applying a second‐stage filter to improve policy decision making
por: Kan, Kaying, et al.
Publicado: (2021)

Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis
por: Albuquerque de Almeida, Fernando, et al.
Publicado: (2022)

Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia
por: Wasir, Riswandy, et al.
Publicado: (2019)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
por: Mfumbilwa, Zakile A., et al.
Publicado: (2023)

Representation in participatory healthcare decision‐making
por: Moore, Emma L., et al.
Publicado: (2022)

PB1947: A META-ANALYTIC ENDPOINT VALIDATION OF SURROGATES USED IN CLINICAL TRIALS EVALUATING THE EFFICACY OF THERAPIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Bahar, Nasim, et al.
Publicado: (2023)

AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
por: Vemer, P., et al.
Publicado: (2015)

Potential barriers and facilitators for implementation of an integrated care pathway for hearing-impaired persons: an exploratory survey among patients and professionals
por: Grutters, Janneke PC, et al.
Publicado: (2007)

Decision models of prediabetes populations: A systematic review
por: Leal, Jose, et al.
Publicado: (2019)

Practices and perspectives of patients and healthcare professionals on shared decision-making in nephrology
por: van Dulmen, Sandra, et al.
Publicado: (2022)

Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints
por: Grutters, Janneke P. C., et al.
Publicado: (2007)

Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach
por: Bouman, A. C., et al.
Publicado: (2015)

Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry
por: Li, Xinyu, et al.
Publicado: (2023)

Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Otten, Thomas, et al.
Publicado: (2022)

Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Otten, Thomas, et al.
Publicado: (2023)

Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer
por: de Boer, Pieter T., et al.
Publicado: (2016)

Countermanding Perceptual Decision-Making
por: Middlebrooks, Paul G., et al.
Publicado: (2019)

Microgravity induces overconfidence in perceptual decision-making
por: Loued-Khenissi, Leyla, et al.
Publicado: (2023)

P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)
por: Thieblemont, Catherine, et al.
Publicado: (2023)

P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Moral reasoning, moral decision‐making, and empathy in Korsakoff’s syndrome
por: Oudman, Erik, et al.
Publicado: (2020)

La decisión de Fidel : recursos para sobrevivir al siglo /
por: Corro, Salvador
Publicado: (1997)

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2016)

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments
por: Petersohn, Svenja, et al.
Publicado: (2019)

Cost-Effectiveness of Four Tobacco Control Interventions in Mongolia
por: Tuvdendorj, Ariuntuya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_akdlto2bqa298nfo3qcghuhf7n